European Academy of Dermatology and Venereology (EADV) 31st Congress

Milan 07 September 2022 - 10 September 2022

Skin biomarkers predict AD risk, severity in newborns

27 Oct 2022 by

Predicting which newborn will go on to develop atopic dermatitis (AD) and how severe it will be is now feasible, according to the BABY* study.

27 Oct 2022

Ruxolitinib improves repigmentation in vitiligo through 52 weeks

21 Oct 2022 by

Long-term use of ruxolitinib cream continued to improve facial and total body repigmentation in patients with nonsegmental vitiligo from 24 to 52 weeks, according to an updated pooled analysis of the phase III TRuE-V1* and TRuE-V2** studies presented at EADV 2022.

21 Oct 2022

Dupilumab reduces itch, improves skin lesions in prurigo nodularis

20 Oct 2022 by

Dupilumab improves itch response and skin lesions in patients with prurigo nodularis (PN) inadequately controlled with prior therapies in the LIBERTY-PN PRIME trial.

20 Oct 2022

Lebrikizumab efficacy in atopic dermatitis maintained at 1 year

12 Oct 2022 by

Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.

12 Oct 2022

Ligelizumab safe, effective in patients with chronic spontaneous urticaria

06 Oct 2022 by

Ligelizumab, a next-generation anti-IgE antibody, is safe and effective in treating patients with H₁-antihistamine (H₁-AH) refractory chronic spontaneous urticaria (CSU), according to two phase III studies presented at EADV 2022.

06 Oct 2022

Deucravacitinib bestows benefits in Asian patients with plaque psoriasis

04 Oct 2022 by

The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.